Dual action antidepressants and some important considerations

Australian and New Zealand Journal of Psychiatry

Volumn 37, Issue 2, 2003, Pages 190-195

  Gupta, Ramesh K ^b   Tiller, John W ^c   Burrows, Graham D ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Phillip Health Centre   (Australia)

^c Albert Road Clinic ^*  (Australia)

Author keywords

Continuation treatment; Dual action antidepresssants; Relapse prevention

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; IMIPRAMINE; MAPROTILINE; MILNACIPRAN; MIRTAZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANORGASMIA; AUTONOMIC DYSFUNCTION; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DYSURIA; FATIGUE; HUMAN; HYPERTENSION; LETHARGY; LIBIDO DISORDER; LONG TERM CARE; MAJOR DEPRESSION; MEDICAL LITERATURE; MEDLINE; METHODOLOGY; NAUSEA; PRESCRIPTION; RECURRENT DISEASE; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SOMNOLENCE; WITHDRAWAL SYNDROME;

ADRENERGIC ALPHA-ANTAGONISTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; HISTAMINE H1 ANTAGONISTS; HUMANS; MIANSERIN; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; WEIGHT GAIN;

EID: 0037648912     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1614.2003.01169.x     Document Type: Review

References (54)

1. Danish University Antidepressant Group. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 1986; 90:131-138.
2. Danish University Antidepressant Group. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Journal of Affective Disorders 1990; 18:289-299.
3. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. Journal of Psychopharmacology 1994; 8:238-249.
4. Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depression Anxiety 1998; 7 (Suppl. 1):11-17.
5. Briley M. The logical evolution towards dual action antidepressants. Drugs in Focus 2001; 3:5-10.
6. Davis R, Wilde MI. Mirtazapine: a review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs 1996; 5:389-402.
7. Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997; 17:10-21.
8. Kasper S, Praschak-Rieder N, Tauscher J et al. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Safety 1997; 17:251-264.
9. Kent JM. SnaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000; 355:911-918.
10. Beique JC, De Montigny C, Blier P et al. Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine. British Journal of Pharmacology 1998; 125:526-532.
11. Rudolph RL, Feiger AD. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. Journal of Affective Disorders 1999; 56:171-181.
12. Thase ME, Nierenberg AA, Keller MB, Panagides J. For the Relapse Prevention Study Group. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. Journal of Clinical Psychiatry 2001; 162:10.
13. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled. Psychopharmacology 1998; 13:63-73.
14. Bremner JD, Smith WT. Org 3770 vs amitriptyline in the continuation treatment of depression: a placebo-controlled trial. European Journal of Psychiatry 1996; 10:5.
15. Shivastava RK, Cohn C, Crowder J et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. Journal of Clinical Psychopharmacology 1994; 14:322-329.
16. Entsuah AR, Rudolph RL, Hackett D, Miska S. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Clinical Psychopharmacology 1996; 11:137-145.
17. Hackett D, Agniar L, Rudolph R. Venlafaxine prevents recurrence of depression (Poster presentation) Presented at the 11th Congress of the European College of Neuropsychopharmacology, Paris, France, 1998.
18. Rouillon F, Berdeaux G, Bisserbe JC et al. Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life. Journal of Affective Disorders 2000; 58:171-180.
19. Hotopf M, Lewis G, Normand C. Are SSRIs a cost-effective alternative to tricyclics? British Journal of Psychiatry 1996; 168:404-409.
20. Pampallona S, Bollini P, Tibaldo G, Kupelnick B, Munizza C. Patient adherence in the treatment of depression. British Journal of Psychiatry 2002; 180:104-109.
21. Moncrieff J. The antidepressant debate. British Journal of Psychiatry 2002; 180:193-194.
22. Montgomery SA, Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. International Clinical Psychopharmacology 1995; 9:33-40.
23. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. Journal of Clinical Psychiatry 1998; 59:502-508.
24. Kasper S, Pletan Y, Solles A, Tourneaux A. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. International Clinical Psychopharmacology 1996; 11 (Suppl. 4):35-39.
25. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 1995; 49:280-294.
26. Mackay FR, Dunn NR, Martin RM, Pearce GL, Freemantle SN, Mann RD. Newer antidepressants: a comparison of tolerability in general practice. British Journal of General Practice 1999; 49:892-896.
27. Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux A, Prost JF. Milnacipran and selective serotonin reuptake inhibitors in major depression. International Clinical Psychopharmacology 1996; 11 (Suppl. 4):41-46.
28. Martin RM, Hilton SR, Kerry SM, Richards NM. General practitioners' perceptions of the tolerability of antidepressant drugs: a comparison of selective serotonin reuptake inhibitors and tricyclic antidepressants. British Medical Journal 1997; 314:646-651.
29. Troy S, Piergies A, Lucki I et al. Venlafaxine pharmacokinetics and pharmacodynamics (abstract). Clinical Neuropharmacology 1992; 15 (Suppl. 1):234B.
30. Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. Journal of Clinical Psychiatry 1999; 60:22-28.
31. Fava M. Weight gain and antidepressents. Journal of Clinical Psychiatry 2000; 61 (Suppl. 11):37-41.
32. Baldwin DS, Birtwistle J. Antidepressant drugs and sexual function: improving the recognition and management of sexual dysfunction in depressed patients. In: Briley M, Montgomery S, eds. Antidepressant therapy at the dawn of the third millennium. London: Martin Dunitz, 1998; 231-253.
33. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. Journal of Clinical Psychopharmacology 1999; 19:67-85.
34. Ernst C, Foldenyi M, Angst J. The Zurich study. XXI. Sexual dysfunction and disturbances in young adults. Data of a longitudinal epidemiological study. European Archives of Psychiatry and Clinical Neurosciences 1993; 243:179-188.
35. Montejo-Gonzales AL, Llorca G, Izquierdo JA et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. Journal of Sex Therapy 1997; 23:176-194.
36. Piazza LA, Markowitz JC, Kocsis JH et al. Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. American Journal of Psychiatry 1997; 54:1757-1759.
37. Shen WW, Hsu JH. Female sexual side-effects associated with selective serotonin reuptake inhibitors: a descriptive clinical study of 33 patients. International Journal of Psychiatry 1995; 25:239-248.
38. Mendels J, Camera A, Sikes C. Sertraline treatment for premature ejaculation. Clinical Psychopharmacology 1995; 15:341-346.
39. Preskorn SH. Comparison of the tolerability of buproprion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline and venlafaxine. Journal of Clinical Psychiatry 1995; 56:1221.
40. Montgomery SA, Prost JF, Solles A, Briley M. Efficacy and tolerability of milnacipran: an overview. International Clinical Psychopharmacology 1996; 11 (Suppl. 4):47-51.
41. Schatzberg AF, Haddad P, Kaplan EM et al. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation consensus panel. Journal of Clinical Psychiatry 1997a; 58 (Suppl. 7):5-10.
42. MacCall C, Callender J. Mirtazapine withdrawal causing hypomania. British Journal of Psychiatry 1999; 175:390.
43. Klesmer J, Sarcevica A, Fomari V. Panic attacks during discontinuation of mirtazepine. Canadian Journal of Psychiatry 2000; 45:570-571.
44. Farah A, Lauer TE. Possible venlafaxine withdrawal syndrome. American Journal of Psychiatry 1996; 153:576.
45. Johnson H, Bouman WP, Lawton J. Withdrawal reaction associated with venlafaxine. British Medical Journal of 1998; 317:787.
46. Parker G, Mitchell P, Wilhelm K et al. Are the new antidepressant drugs as effective as established physical treatments? Results from an Australasian clinical panel review. Australian and New Zealand Journal of Psychiatry 1999; 33:874-881.
47. Parker G, Hadzi Pavlovic D, Wilhelm K et al. Defining melancholia: properties of refined sign-based measure. British Journal of Psychiatry 1994; 164:316-326.
48. Barbui C, Hotopf M. Amitriptyline v. the rest: still the leading antidepressant after 40 years of randomized controlled trials. British Journal of Psychiatry 2001; 178:129-144.
49. Lin KM. Biological differences in depression and anxiety across races, ethnic groups. Journal of Clinical Psychiatry 2001; 62 (Suppl. 13):13-19; discussion 20-1.
50. Wang JF, Bown CD, Chen B, Young LT. Identification of mood stabilizer-regulated genes by differential-display PCR. International Journal of Neuropsychopharmacology 2001; 4:65-74.
51. Lesch K, Heils A. Serotonergic gene transcriptional control regions: targets for antidepressant drug development? International Journal of Neuropsychopharmacology 2000; 3:67-79.
52. Cassano GB, Musetti L, Soriani A, Savino M. The Pharmacological treatment of Depression: Drug selection Criteria. Pharmacopsychiatry 1993; 26 (Suppl. 1):17-23.
53. Paykel ES, Priest RG. Recognition and management of depression in general practice: consensus statement. British Medical Journal 1992; 305:1198-1202.
54. Kupfer DJ, Frank E, Perel JM et al. Five-year outcome for maintenance therapies in recurrent. Archives of General Psychiatry 1992; 9:767-773.